Research Article

Downregulation of S100 Calcium Binding Protein A9 in Esophageal Squamous Cell Carcinoma

Harsh Pawar,1,2,3,4 Srinivas M. Srikanth,1,5 Manoj Kumar Kashyap,1,6,7,8 Gajanan Sathe,1 Sandip Chavan,1 Mukul Singal,9 H. C. Manju,3 Kariyanakatte Veeraiah Veerendra Kumar,10 M. Vijayakumar,10 Ravi Sirdeshmukh,1 Akhilesh Pandey,6,7,11,12 T. S. Keshava Prasad,1,5 Harsha Gowda,1 and Rekha V. Kumar3

1 Institute of Bioinformatics, International Technology Park, Bangalore 560066, India
2 Rajiv Gandhi University of Health Sciences, Bangalore 560041, India
3 Department of Pathology, Kidwai Memorial Institute of Oncology, Bangalore 560029, India
4 Department of Zoology, Savitribai Phule Pune University, Ganeshkhind, Pune, Maharashtra 411007, India
5 Centre of Excellence in Bioinformatics, School of Life Sciences, Pondicherry University, Pondicherry 605014, India
6 McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
7 Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
8 Moores Cancer Center, University of California, San Diego, La Jolla, CA 92039-0960, USA
9 Government Medical College and Hospital, Sector 32, Chandigarh 160030, India
10 Department of Surgical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560029, India
11 Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
12 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Correspondence should be addressed to Harsha Gowda; harsha@ibioinformatics.org and Rekha V. Kumar; rekha_v_kumar@yahoo.co.in

Received 18 June 2015; Accepted 16 November 2015

Academic Editor: Emidio Scarpellini

Copyright © 2015 Harsh Pawar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The development of esophageal squamous cell carcinoma (ESCC) is poorly understood and the major regulatory molecules involved in the process of tumorigenesis have not yet been identified. We had previously employed a quantitative proteomic approach to identify differentially expressed proteins in ESCC tumors. A total of 238 differentially expressed proteins were identified in that study including S100A9 as one of the major downregulated proteins. In the present study, we carried out immunohistochemical validation of S100A9 in a large cohort of ESCC patients to determine the expression and subcellular localization of S100A9 in tumors and adjacent normal esophageal epithelia. Downregulation of S100A9 was observed in 67% (n = 192) of 288 different ESCC tumors, with the most dramatic downregulation observed in the poorly differentiated tumors (99/111). Expression of S100A9 was restricted to the prickle and functional layers of normal esophageal mucosa and localized predominantly in the cytoplasm and nucleus whereas virtually no expression was observed in the tumor and stromal cells. This suggests the important role that S100A9 plays in maintaining the differentiated state of epithelium and suggests that its downregulation may be associated with increased susceptibility to tumor formation.

1. Introduction

Esophageal squamous cell carcinoma (ESCC) is more common in developing countries including India and China [1]. The incidence of ESCC is more common in males, with the male:female ratio being 2:1 [2–4]. The major risk factors associated with ESCC include alcohol consumption and tobacco usage [5–8]. Other dietary risk factors include ingestion of mycotoxins, salted food, smoked foods, and deficiency of essential micronutrients such as vitamin A and zinc [9].
Si100A9 belongs to the S100 family of genes that includes 17 members located within the epidermal differentiation complex (EDC) as a cluster on chromosome 1q21 locus [10–13]. These functionally related genes are involved in terminal epidermal differentiation [14] and loss of heterozygosity (LOH) is frequently observed at 1q21 locus [15]. Si100A9 is a protein of 114 amino acids, which forms a heterodimer with another Si100 protein Si100A8. This 24 kDa heterodimeric complex is commonly known as calprotectin [16]. Si100A9 is sometimes also referred as migration inhibitory factor related protein 14 (MRP14) or calgranulin B (CAGB).

Si100A9 has been shown to be upregulated in various cancers such as squamous cancers of the skin [17], breast ductal carcinoma [18], lung cancer [19], bladder cancer [20, 21], and prostate adenocarcinoma [22]. However, Si100A9 has been reported to be downregulated in head and neck squamous cell carcinoma (HNSCC) [23]. Various studies in the past have identified Si100A9 to be predominantly downregulated in esophageal cancer. Previous gene expression studies from other groups [24] as well as from our own group have shown Si100A9 to be downregulated in ESCC [25]. The majority of the studies have been carried out in Chinese ESCC patients and these studies provide valuable insights into the downregulation of Si100 genes/proteins including Si100A9 in ESCC. These studies include transcriptomic analysis [24], differential gene expression analysis [26], differential display RT-PCR [27], and immunohistochemistry [28]. Transcriptomic and proteomic studies in Indian ESCC patients have also shown downregulation of Si100A9 [25, 29]. There are no reports of Si100A9 IHC study on ESCC in Indian patients.

In total, 4 unique peptides were identified mapping to Si100A9, resulting in 45% coverage of Si100A9. Figure I provides information regarding Si100A9 protein structure and MS/MS spectra of peptides identified in the previous quantitative proteomic study [25, 29]. Hence, we selected this protein for further validation by immunohistochemical labeling of tumor and adjacent normal tissue from a larger cohort of ESCC cases.

2. Materials and Methods

2.1. Tissue Samples. Immunohistochemistry (IHC) was carried out on a large number of samples using tissue microarrays (TMAs) (n = 200) and tissue sections (tumor and adjacent normal epithelia) from ESCC patients of Indian origin (n = 100). Commercially available TMAs were obtained from following vendors: (i) US Biomax, Inc. (Rockville, MD; Catalog numbers ES1201, ES1202, and ES801) consisting of 160 ESCC cases with matched adjacent normal esophageal epithelia. The ESCC tumors varied from Grade I to Grade III and were obtained from patients in the age group of 36 to 78 years and (ii) FolioBio (Powell, OH; Catalog numbers ARY-HH0091) consisting of 160 ESCC cases with matched adjacent normal esophageal epithelia. The ESCC tumors varied from Grade I to Grade III and were obtained from patients in the age group of 43 to 76 years. Of the purported 200 cases on TMAs, 12 cases were found to have either missing tumor or corresponding normal core and were thus not included in the analysis. Of the 188 evaluable ESCC cases from TMAs, 29 cases were well differentiated, 113 cases
were moderately differentiated, and 46 cases were poorly differentiliated squamous carcinomas. Additionally, of the 100 Indian ESCC cases, 7 cases were well differentiated, 28 cases were moderately differentiated, and 65 cases were poorly differentiated squamous carcinomas.

Archived formalin-fixed paraffin embedded (FFPE) tissue blocks of ESCC samples and adjacent normal epithelium \((n = 100)\) were obtained from the Department of Pathology, Kidwai Memorial Institute of Oncology (KMIO), Bangalore, India. Details of gender, age, and use of tobacco and alcohol were obtained from archived case records. Five ESCC cases were used to standardize the SI00A9 antibody dilution and determine the staining pattern before large-scale validation on TMA and tissue sections. An ethical clearance was obtained from the Ethical Committee of KMIO, Bangalore.

2.2. Immunohistochemical Staining for Study of SI00A9 Expression. A rabbit polyclonal SI00A9 antibody was purchased from Santa Cruz Biotechnology (Catalog number sc-20173). According to the manufacturer, the immunogen (antigen) used to generate the SI00A9 antibody was a 90-amino-acid-long, recombinant human SI00A9 protein fragment mapping to the C-terminus of SI00A9. The optimum dilution of the SI00A9 antibody was determined on noncancerous cervical squamous epithelium obtained from the tumor-free margins of resected cervical cancer specimens, respectively. Various antibody dilutions \((1:100, 1:250, 1:500, 1:1000,\) and \(1:1500)\) were tested before deciding on \(1:1000\) as the optimal dilution based on intensity of staining as well as absence of nonspecific background staining. The staining pattern of normal esophageal squamous epithelium \((n = 5)\) and ESCC tumor sections \((n = 5)\) was then verified before large-scale immunostaining.

An Envision kit (Dako, Glostrup, Denmark) was used according to the manufacturer’s instructions. The IHC staining procedure was carried out as previously described [30]. Briefly, the FFPE tissues were deparaffinized and subjected to antigen retrieval which was carried out by heating the tissue sections for 20 minutes at 100°C in antigen retrieval buffer (citrate buffer pH 6.0) using an electric steamer (Croma, India). This was followed by quenching of endogenous peroxidases by using the blocking solution (ready to use from Dako, Glostrup, Denmark) followed by three washes with the wash buffer. The sections were incubated with the primary antibody overnight at 4°C in a humidified chamber. After washing, the slides were incubated with horseradish peroxidase conjugated secondary antibody (Vector labs, Burlingame, CA) for 30 minutes at room temperature. The staining was developed for 5 minutes using DAB chromogen (Dako, Glostrup, Denmark), followed by counterstaining with Harris hematoxylin (Nice Chemicals, Kochi, India). Immunohistochemical staining was assessed by an experienced pathologist (RVK), who was blinded to the clinical and pathological data.

The staining was scored based on modified McCarty’s \(H\)-scoring system, which takes into account the percentage of positive cells and the intensity of staining to provide a total score varying from 0 to 300. The “\(H\)-score” is a semiquantitative method of assessing the extent of immunostaining.

For big tissue sections, a total of 10 fields were screened and examined at 400x magnification and in the TMA cores, all cells were counted. The staining was designated as negative \((H\text{-score} < 49)\), weakly positive \((1+; \ H\text{-score} = 50–99)\), moderately positive \((2+; \ H\text{-score} = 100–199)\), or strongly positive \((3+; \ H\text{-score} = 201–300)\). A comparison was made between the intensity of the staining of normal esophageal epithelium and that of carcinoma cells. Noncancerous cervical squamous epithelium sections (as suggested by the manufacturer) obtained from the tumor-free margins of resected cervical cancer specimens, respectively, were used as positive controls for SI00A9. Noncancerous squamous epithelium where the diluent (phosphate buffered saline pH 7.5) was used instead of the primary antibody served as negative controls. Negative and positive controls were used with each IHC run.

The statistical significance of the differential staining observed was determined using a Chi-square test and Fischer’s exact test. Results for SI00A9 expression were considered statistically significant only if the \(p\) value was <0.05. The statistical analysis was carried out using R version R-2.13 (R Foundation for Statistical Computing, Vienna, Austria).

3. Results and Discussion

3.1. Clinical Details. In this study, we have investigated 288 ESCC cases represented by TMAs \((n = 188)\) and whole tissue sections from Indian ESCC patients \((n = 100)\). The mean age of all patients was 56.5 years while median age was 57 years (range 32–80 years). Of these, 200 were males and 88 were females. Further clinical details were available only for the 100 Indian patients, from patient records. Of these, 91% were from the low socioeconomic group. The use of alcohol and tobacco was noted in 26% and 45%, respectively, in men (67/100), with no record of extent of usage.

3.2. Expression of SI00A9 in ESCC. Expression of SI00A9 in normal esophageal epithelium showed restriction of immunostaining to the prickle and functional layers. Staining was predominantly localized in the cytoplasm and nucleus of epithelial cells in these layers. The basal layer (BL) did not show expression of SI00A9. Expression of SI00A9 was observed in 95% (237/288) of normal esophageal epithelium (Figure 2(a)).

In 89% (99/111) of Grade III ESCCs (poorly differentiated tumors), SI00A9 showed no detectable or weak expression in the epithelial cells (Figure 2(b)). However, sporadic staining could be seen in 11% (12/111) in the regions that were better differentiated, depending on the amount of keratinization. Likewise, keratinized foci in the well differentiated tumors, Grades I (36/36) and II (48/141), also showed immunostaining (Figure 3). The intensity of staining varied with the level of keratinization and presence of keratin pearls. The majority of Grades I and II tumors had 30%–50% of keratinized cells within the tumor. These keratinized tumor cells showed moderate to strong expression of SI00A9. Additionally, SI00A9 immunostaining was not observed in the regenerative basal layer in Grade I tumors. The positive controls (normal cervical squamous epithelium) showed moderate to strong
Figure 2: Expression of S100 calcium binding protein A9 in normal esophageal squamous epithelium and ESCC. (a) Expression of S100A9 in representative normal esophageal squamous epithelium where the expression of S100A9 (brown color) was limited to the differentiated prickle and functional layers, with no expression in the regenerative basal layer. Immunostaining pattern was cytoplasmic and nuclear. (b) Expression of S100A9 in ESCC tissue sections. S100A9 expression was undetectable in the majority of tumor cells and stroma. All the images were acquired at 200x and 400x magnification. Scale bars = 50 μm and 20 μm.
cytoplasmic and/or nuclear immunostaining (Figure 4(a)). The negative controls did not show immunostaining for S100A9 (Figure 4(b)).

3.3. Statistical Analysis. No correlation was seen between expression of S100A9 in tumors in relation to age and gender. There was statistically significant ($p < 0.05$) difference in the expression of S100A9 between tumors and normal tissues within a 95% confidence interval. The IHC staining pattern in tumors and normal tissues is summarized in Table 1 and the differential staining pattern of S100A9 in various histopathological Grades of ESCC is summarized in Table 2. The IHC scores for S100A9 in all ESCC cases are provided in Supplementary Table 1 (see Supplementary Material available online at http://dx.doi.org/10.1155/2015/325721).

3.4. Public Availability and Accessibility of IHC Data. To make our observations publicly available and accessible to other researchers, we have submitted our data on the IHC expression of S100A9 in normal esophageal epithelia (http://www.humanproteinpedia.org/Experimental_details?exp_id=TE-143441) and ESCC (http://www.humanproteinpedia.org/Experimental_details?can_id=105420) to Human Proteinpedia. The data pertaining to the peptides identified for S100A9 was also submitted to Human Proteinpedia (HUPA; http://www.humanproteinpedia.org/) [31]. Figure 5 shows a screenshot of Human Protein Reference Database (HPRD; http://www.hprd.org/) [32] page for S100A9 protein and also of the HUPA resource displaying S100A9 expression in ESCC and normal esophageal epithelia.

Normal epithelial growth and differentiation frequently involve activation and repression of genes including calcium binding S100 genes [33]. However, disruption of this process leads to dedifferentiation of epithelial cells resulting in carcinogenesis. It is becoming clear that S100A9 is involved in calcium mediated signaling pathways and may also be involved in binding to keratins [34, 35], cell cycle control [36], inflammation [37], cellular differentiation [38, 39], stress response [40], and promoting apoptosis via zinc sequestration [41, 42]. S100A9 has been shown to be a transcriptional target of TP53 mediated regulation and it can induce apoptosis in a TP53 dependent manner as promoter region of S100A9 gene has been shown to have a TP53 response element. In addition, S100A9 knockdown resulted in impaired apoptosis.

Figure 3: Expression of S100 calcium binding protein A9 in Grade I ESCC. S100A9 expression was observed in the foci of keratinization (keratin pearls) in Grade I tumors with cytoplasmic and nuclear localization. The degree of S100A9 immunostaining varied with the level of keratinization in tumor cells. Stroma showed no S100A9 expression. All the images were acquired at 200x and 400x magnification. Scale bars = $50 \mu m$ and $20 \mu m$.

Table 1: Summary of IHC labeling for S100 calcium binding protein A9 (S100A9) in normal and ESCC tissues.

| Parameters | Normal | ESCC |
|------------|--------|------|
| (1) Positive | 273 | 96 |
| (a) Strong ($H$-score 200–300) | 84 | 4 |
| (b) Moderate ($H$-score 100–199) | 112 | 16 |
| (c) Weak ($H$-score 50–99) | 77 | 76 |
| (2) Negative ($H$-score 0–49) | 15 | 192 |
| (3) $p$ value | <0.001 |

$N = 288$. 

The negative controls did not show immunostaining for S100A9 (Figure 4(b)).
Table 2: Correlation between histopathological characteristics and S100A9 immunohistochemical staining in ESCC.

| Characteristic             | Cases | No expression | Expression | p value |
|---------------------------|-------|---------------|------------|---------|
| Total                     | 288   | 192           | 96         | <0.01   |
| Age                       |       |               |            |         |
| ≥56 years                 | 140   | 89            | 51         | —       |
| <56 years                 | 148   | 105           | 43         | —       |
| Gender                    |       |               |            |         |
| Males                     | 200   | 139           | 61         | —       |
| Females                   | 88    | 54            | 34         | —       |
| Pathological grade        |       |               |            |         |
| Well differentiated        | 36    | —             | 36         | <0.01   |
| Moderately differentiated  | 141   | 93            | 48         | —       |
| Poorly differentiated      | 111   | 99            | 12         |         |

Figure 4: Expression of S100 calcium binding protein A9 in positive and negative controls. (a) Positive controls (normal cervical squamous epithelium) where strong to moderate expression of S100A9 was limited to the differentiated prickle and functional layers with no immunostaining of the regenerative basal layer. Expression of S100A9 was cytoplasmic and nuclear. (b) Negative controls (normal cervical squamous epithelium) without the addition of the anti-S100A9 antibody. All the images were acquired at 200x magnification and 400x. Scale bars = 50 μm and 20 μm.

mediated by TP53 [43]. Thus, it appears that S100A9 can regulate cell cycle progression and act as a tumor suppressor in esophageal squamous epithelium. We had previously shown the subcellular localization of another calcium binding protein cornulin (CRNN) to be downregulated in ESCC [30]; the role of cornulin was not known in esophageal epithelium. In a recent study by Chen et al. it was shown that cornulin is a potential tumor suppressor and it regulates cell cycle progression at G1/S checkpoint by upregulating P21WAF1/CIP1 and Rb. Thus it exerts its tumor suppressor effect by inhibiting G1 to S phase transition in cell cycle [44].

The esophageal squamous epithelium is constantly exposed to irritants/toxic compounds as well as pathogens such as herpes simplex virus (HSV) [45]. Stress induced by various environmental factors like zinc deficiency, alcohol consumption, nitrosamines, or pathogens may
result in transient overexpression of S100A9 in epithelia as a protective inflammatory response [46]. This initial event results in increased activity of metabolic enzymes such as cyclooxygenases, which can result in metabolic activation of carcinogens. This results in mutation of TP53, which regulates S100A9 expression; hence S100A9 is frequently downregulated in ESCC. Apoptosis mediated cell death in disease is a protective mechanism for removing mutated cells. However, zinc deficiency may lead to disruption of this process thus resulting in ESCC tumor formation [24]. Thus S100A9 seems to play a crucial role in cell cycle progression and cellular differentiation as well as apoptosis in squamous epithelium.

In the current study, we performed immunohistochemical analysis to determine the expression of S100A9 in ESCC tumors (different Grades) and matched adjacent normal epithelia. The expression of S100A9 was found to be downregulated in the majority of poorly differentiated ESCCs (Grade III tumors). However, expression of S100A9 was restricted only to keratinized foci or keratin pearls in Grade I/II tumors with abundant cytoplasmic keratins. In case of normal esophageal epithelium, the strong cytoplasmic and nuclear expression of S100A9 was observed in the majority of esophageal epithelia and it was localized to the differentiated layers (prickle and functional). The regenerative basal layer showed no expression of S100A9. These evidences reveal that S100A9 expression is restricted to the differentiated layers and its expression is lost during the tumor development.

4. Conclusion

In this study, we have examined the downregulation of S100A9 at the protein level in the largest cohort of ESCC cases to date using IHC, which correlates with our previous findings from global transcriptomic and proteomic analyses. Downregulation of S100A9 in ESCC and HNSCC is in contrast to that observed in several other tumors where this protein is found to be upregulated. The present study confirms the downregulation of S100A9 in a large cohort of ESCC patients. Interestingly, S100A9 expression correlated with the histological Grade of tumor with a more dramatic downregulation observed in poorly differentiated tumors. This points to an important role that S100A9 plays in maintaining the differentiated state of epithelium and suggests that its downregulation may be associated with increased susceptibility to tumor
formation. However, additional studies will be required to fully elucidate its role in the pathogenesis of ESCC.

**Abbreviations**

EDC: Epidermal differentiation complex  
ESCC: Esophageal squamous cell carcinoma  
iTRAQ: Isobaric tags for relative and absolute quantitation  
LOH: Loss of heterozygosity  
S100A9: S100 calcium binding protein A9.

**Conflict of Interests**

All the authors declare no conflict of interests.

**Authors’ Contribution**

Harsh Pawar carried out IHC and wrote the paper. Srinivas M. Srikanth helped in uploading IHC images and data to Human Proteinpedia and helped with the statistical analysis. Manoj Kumar Kashyap provided critical inputs to paper and study. Sandip Chavan, Gajanan Sathe, and Mukul Singal helped during the IHC process and also assisted with the photomicrography of IHC stained sections. Mukul Singal, H. C. Manju helped during the scoring of IHC stained TMA and helped in preparing tissue sections slides for 100 Indian ESCC patients. Kariyanakatte Veeraiah Veerendra Kumar and M. Vijayakumar are surgeons and provided the samples. Ravi Sirdeshmukh, Harsha Gowda, and T. S. Keshava Prasad provided valuable inputs to the study and paper. Rekha V. Kumar scored the IHC stained slides and provided critical inputs for the study and Akhilesh Pandey provided the critical inputs for the design of the study and for the paper.

**Acknowledgments**

The authors thank the Department of Biotechnology (DBT), Government of India, for research support to the Institute of Bioinformatics. T. S. Keshava Prasad and Rekha V. Kumar are supported by DBT grant (DBT/CSH/GIA/1583/2010-2011). Dr. Harsha Gowda is a Wellcome Trust/DBT India Alliance Early Career Fellow. Dr. Harsh Pawar is a recipient of UGC Dr. D. S. Kothari Postdoctoral Fellowship from University Grants Commission, Government of India, under the guidance of Professor Kalpana Pai, Department of Zoology, Savitribai Phule Pune University. Gajanan Sathe and Sandip Chavan are recipients of Senior Research Fellowship from Council of Scientific and Industrial Research (CSIR), Government of India. Srinivas M. Srikanth is a recipient of Junior Research Fellowship from University Grants Commission (UGC), Government of India. The authors would like to thank Drs. S. K. Shankar and Anita Mahadevan of National Institute of Mental Health and Neurological Sciences (NIMHANS), for providing access to the imaging facility.

**References**

[1] G. D. Eslick, “Epidemiology of esophageal cancer,” *Gastroenterology Clinics of North America*, vol. 38, no. 1, pp. 17–25, 2009.
[2] J. V. Cheria, R. Sivaraman, A. K. Muthusamy, and V. Jayanthi, “Carcinoma of the esophagus in Tamil Nadu (South India): 16-year trends from a tertiary center,” *Journal of Gastrointestinal and Liver Diseases*, vol. 16, no. 3, pp. 245–249, 2007.
[3] S. Zheng, L. Vuitton, I. Shyehidin, D. A. Vuitton, Y. Zhang, and X. Lu, “Northwestern China: a place to learn more on esophageal cancer. Part one: behavioural and environmental risk factors,” *European Journal of Gastroenterology and Hepatology*, vol. 22, no. 8, pp. 917–925, 2010.
[4] B. Ziaian, V. Montazeri, R. Khazaiee, S. Amini, M. Karimi, and D. Mehrabani, “Esophageal cancer occurrence in Southeastern Iran,” *International Journal of Research in Medical Sciences*, vol. 15, no. 5, pp. 290–291, 2010.
[5] M. S. Khuroo, S. A. Zargar, R. Mahajan, and M. A. Banday, “High incidence of oesophageal and gastric cancer in Kashmir in a population with special personal and dietary habits,” *Gut*, vol. 33, no. 1, pp. 11–15, 1992.
[6] N. A. Khan, M. A. Teli, M. Mohib-Ul Haq, G. M. Bhat, M. M. Lone, and F. Afroz, “A survey of risk factors in carcinoma esophagus in the valley of Kashmir, Northern India,” *Journal of Cancer Research and Therapeutics*, vol. 7, no. 1, pp. 15–18, 2011.
[7] S. Chitra, L. Ashok, L. Anand, S. Vijaya, and V. Jayanthi, “Risk factors for esophageal cancer in Coimbatore, southern India: a hospital-based case-control study,” *Indian Journal of Gastroenterology*, vol. 23, no. 1, pp. 19–21, 2004.
[8] A. Znaor, P. Brennan, V. Gajalakshmi et al., “Independent and combined effects of tobacco smoking, chewing and alcohol drinking on the risk of oral, pharyngeal and esophageal cancers in Indian men,” *International Journal of Cancer*, vol. 105, no. 5, pp. 681–686, 2003.
[9] N. A. Dar, M. M. Mir, I. Salam et al., “Association between copper excess, zinc deficiency, and TP53 mutations in esophageal squamous cell carcinoma from Kashmir Valley, India—a high risk area,” *Nutrition and Cancer*, vol. 60, no. 5, pp. 585–591, 2008.
[10] B. W. Schäfer, R. Wicki, D. Engelkamp, M.-G. Mattei, and C. W. Heizmann, “Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family,” *Genomics*, vol. 25, no. 3, pp. 638–643, 1995.
[11] I. Marenholz, A. Volz, A. S. Ziegler et al., “Genetic analysis of the epidermal differentiation complex (EDC) on human chromosome 1q21: chromosomal orientation, new markers, and a 6-Mb YAC contig,” *Genomics*, vol. 37, no. 3, pp. 295–302, 1996.
[12] D. Mischke, B. P. Korge, I. Marenholz, A. Volz, and A. Ziegler, “Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex (‘epidermal differentiation complex’) on human chromosome 1q21,” *Journal of Investigative Dermatology*, vol. 106, no. 5, pp. 989–992, 1996.
[13] D. Engelkamp, B. W. Schäfer, M. G. Mattei, P. Erne, and C. W. Heizmann, “Six S100 genes are clustered on human chromosome 1q21: identification of two genes coding for the two previously unreported calcium-binding proteins S100D and S100E,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 90, no. 14, pp. 6547–6551, 1993.
[14] M. Lioumi, M. G. Olavesen, D. Nizetic, and J. Ragoussis, “High-resolution YAC fragmentation map of 1q21,” *Genomics*, vol. 49, no. 2, pp. 200–208, 1998.
[15] J. Li, Z. Liu, Y. Wang et al., “Allelic imbalance of chromosome 1q in esophageal squamous cell carcinomas from China: a novel region of allelic loss and significant association with differentiation,” Cancer Letters, vol. 220, no. 2, pp. 221–230, 2005.

[16] I. Stříž and I. Trebichavský, “Calprotectin—a pleiotropic molecule in acute and chronic inflammation,” Physiological Research, vol. 53, no. 3, pp. 245–253, 2004.

[17] J.-E. Dazard, H. Gal, N. Amariglio, G. Rechavi, E. Domany, and D. Givol, “Genome-wide comparison of human keratinocyte and squamous cell carcinoma responses to UVB irradiation: implications for skin and epithelial cancer,” Oncogene, vol. 22, no. 19, pp. 2993–3006, 2003.

[18] K. Ara, S. Take, T. Teratani, Y. Ito, T. Yamada, and R. Nozawa, “S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast,” Current Cancer Drug Targets, vol. 8, no. 4, pp. 243–252, 2008.

[19] Y.-J. Su, F. Xu, J.-P. Yu, D.-S. Yue, X.-B. Ren, and C.-L. Wang, “Up-regulation of the expression of S100A8 and S100A9 in lung adenocarcinoma and its correlation with inflammation and other clinical features,” Chinese Medical Journal, vol. 123, no. 16, pp. 2215–2220, 2010.

[20] R. Yao, A. Lopez-Beltran, G. M. Maclellan, R. Montironi, J. N. Ebble, and L. Cheng, “Expression of S100 protein family members in the pathogenesis of bladder tumors,” Anticancer Research, vol. 27, pp. 3051–3058, 2007.

[21] S. Minami, Y. Sato, T. Matsumoto et al., “Proteomic study of sera from patients with bladder cancer: usefulness of S100A8 and S100A9 proteins,” Cancer Genomics and Proteomics, vol. 7, no. 4, pp. 181–190, 2010.

[22] S. Grebhardt, C. Veltkamp, P. Ströbel, and D. Mayer, “Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer,” International Journal of Cancer, vol. 131, no. 12, pp. 2785–2794, 2012.

[23] H. E. Gonzalez, M. Gujrat, M. Frederick et al., “Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma,” Archives of Otolaryngology—Head and Neck Surgery, vol. 129, no. 7, pp. 754–759, 2003.

[24] A. Luo, J. Kong, G. Hu et al., “Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarrays,” Oncogene, vol. 23, no. 6, pp. 1291–1299, 2004.

[25] M. K. Kashyap, A. Marimuthu, C. J. H. Kishore et al., “Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers,” Cancer Biology and Therapy, vol. 8, no. 1, pp. 34–46, 2009.

[26] J. Ji, L. Zhao, X. Wang et al., “Differential expression of S100 gene family in human esophageal squamous cell carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 8, pp. 480–486, 2004.

[27] J. Wang, Y. Cai, H. Xu et al., “Expression of MRPI4 gene is frequently down-regulated in Chinese human esophageal cancer,” Cell Research, vol. 14, no. 1, pp. 46–53, 2004.

[28] J.-P. Kong, F. Ding, C.-N. Zhou et al., “Loss of myeloid-related protein 8 and myeloid-related proteins 14 expression in human esophageal squamous cell carcinoma correlates with poor differentiation,” World Journal of Gastroenterology, vol. 10, no. 8, pp. 1093–1097, 2004.

[29] H. Pawar, M. K. Kashyap, N. A. Sahasrabuddhe et al., “Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery,” Cancer Biology and Therapy, vol. 12, no. 6, pp. 510–522, 2011.

[30] H. Pawar, J. Maharudraiah, M. K. Kashyap et al., “Downregulation of cornulin in esophageal squamous cell carcinoma,” Acta Histochemica, vol. 115, no. 2, pp. 89–99, 2013.

[31] S. Mathivanan, M. Ahmed, N. G. Ahn et al., “Human Proteinpedia enables sharing of human protein data,” Nature Biotechnology, vol. 26, pp. 164–167, 2008.

[32] S. Peri, J. D. Navarro, T. Z. Kristiansen et al., “Human protein reference database as a discovery resource for proteomics,” Nucleic Acids Research, vol. 32, pp. D497–D501, 2004.

[33] N. Sato and J. Hitomi, “S100P expression in human esophageal epithelial cells: human esophageal epithelial cells sequentially produce different S100 proteins in the process of differentiation,” Anatomical Record, vol. 267, no. 1, pp. 60–69, 2002.

[34] M. Goebeler, J. Roth, C. van den Bos, G. Ader, and C. Sorg, “Increase of calcium levels in epithelial cells induces translocation of calcium-binding proteins migration inhibitory factor-related protein 8 (MRP8) and MRP14 to keratin intermediate filaments,” Biochemical Journal, vol. 309, no. 2, pp. 419–424, 1995.

[35] I. S. Thorley, J. Roth, J. Regenbogen et al., “The Ca2+-binding proteins S100A8 and S100A9 are encoded by novel injury-regulated genes,” The Journal of Biological Chemistry, vol. 276, no. 38, pp. 35818–35825, 2001.

[36] S. Tugizov, J. Berline, R. Herrera, M. E. Penaranda, M. Nakagawa, and J. Palefsky, “Inhibition of human papillomavirus type 16 E7 phosphorylation by the S100 MRP-8/14 protein complex,” Journal of Virology, vol. 79, no. 2, pp. 1099–1112, 2005.

[37] C. Taccioli, H. Chen, Y. Jiang et al., “Dietary zinc deficiency fuels esophageal cancer development by inducing a distinct inflammatory signature,” Oncogene, vol. 31, no. 42, pp. 4550–4558, 2012.

[38] A. Voss, G. Bode, C. Sopalla et al., “Expression of S100A8/A9 in HaCaT keratinocytes alters the rate of cell proliferation and differentiation,” FEBS Letters, vol. 585, no. 2, pp. 440–446, 2011.

[39] H. Martinsson, M. Yhr, and C. Enerbäck, “Expression patterns of S100A7 (psoriasin) and S100A9 (calgranulin-B) in keratinocyte differentiation,” Experimental Dermatology, vol. 14, no. 3, pp. 161–168, 2005.

[40] H. Carlsson, M. Yhr, S. Pettersson, N. Collins, K. Polyak, and C. Enerbäck, “Psoriasin (S100A7) and calgranulin-B (S100A9) induction is dependent on reactive oxygen species and is downregulated by Bcl-2 and antioxidants,” Cancer Biology and Therapy, vol. 4, no. 9, pp. 998–1005, 2005.

[41] S. Ghavami, C. Kerkhoff, M. Los, M. Hashemi, C. Sorg, and F. Karam-Tehrani, “Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions,” Journal of Leukocyte Biology, vol. 76, no. 1, pp. 169–175, 2004.

[42] S. Yui, Y. Nakatani, M. J. Hunter, W. J. Chazin, and M. Yamazaki, “Implication of extracellular zinc exclusion by recombinant human calprotectin (MRP8 and MRP14) from target cells in its apoptosis-inducing activity,” Mediators of Inflammation, vol. 11, no. 3, pp. 165–172, 2002.

[43] C. Li, H. Chen, F. Ding et al., “A novel p53 target gene, S100A9, induces p53-dependent cellular apoptosis and mediates the p53 apoptosis pathway,” Biochemical Journal, vol. 422, no. 2, pp. 363–372, 2009.

[44] K. Chen, Y. Li, Y. Dai et al., “Characterization of tumor suppressive function of cornulin in esophageal squamous cell carcinoma,” PLoS ONE, vol. 8, no. 7, Article ID e68838, 2013.
[45] A. Voss, K. Gescher, A. Hensel, W. Nacken, K. S. Zänker, and C. Kerkhoff, “Double-stranded RNA induces S100 gene expression by a cycloheximide-sensitive factor,” FEBS Letters, vol. 586, no. 2, pp. 196–203, 2012.

[46] S.-G. Wan, C. Taccioli, Y. Jiang et al., “Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression,” International Journal of Cancer, vol. 129, no. 2, pp. 331–345, 2011.